The startup has developed a biotechnology platform that constructs synthetic minimal cells using a biochemical mix of proteins capable of gene transcription and translation, along with a DNA program. This technology enables medical researchers to detect low-abundance molecular markers and cells, facilitating advancements in diagnostics and therapeutic development.
Funding
$700K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for conditions like alcohol poisoning primarily address symptoms, often resulting in extended periods of high blood alcohol levels and prolonged recovery. Existing cancer therapies may lack precision, leading to systemic toxicity and reduced efficacy in targeting solid tumors.
Solution
Synlife is developing synthetic cell-based therapeutics to address unmet medical needs. Their technology utilizes liposomes containing engineered systems of macromolecules, such as highly active enzymes composing metabolic pathways, to mimic cellular functions. These synthetic cells can be deployed to augment metabolism at targeted sites or throughout the body. Synlife's lead formulation, SOBER, aims to rapidly remove ethanol from the blood of alcohol poisoning patients. Another formulation is being developed as a combination therapy for solid tumors, using synthetic cells to convert chemotherapeutic drug precursors into their active forms directly at the tumor site, enhancing tumor cell killing while minimizing systemic exposure.
Target Audience
Synlife's primary target audience includes medical researchers and clinicians focused on developing novel therapeutics for alcohol poisoning and solid tumor cancers.
Features
- Synthetic cells constructed from liposomes containing complex systems of macromolecules.
- Engineered metabolic pathways within synthetic cells for targeted therapeutic applications.
- SOBER formulation designed for rapid ethanol removal in alcohol poisoning cases.
- Synthetic cell-based combination therapy for solid tumors, enhancing local drug activation.
- Potential for increased therapeutic efficacy and reduced systemic toxicity compared to conventional treatments.